Drugs / Firategrast
Firategrast
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01416363 | May → Sep 2011 | relapsing-remitting multiple sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01424462 | Apr → Jul 2010 | relapsing-remitting multiple sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00548769 | Apr → Nov 2007 | multiple sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT00469378 | Jul 2007 → May 2009 | multiple sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00395317 | Dec 2006 → Aug 2009 | multiple sclerosis | GlaxoSmithKline | Completed | Met primary |
| Phase 2 | NCT00097331 | Sep 2004 → Jul 2006 | relapsing-remitting multiple sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | firategrast | “Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.” NCT01424462 ↗4“Formulation A will contain firategrast drug substance from native drug batch Irvine.” NCT00548769 ↗ |
| Known as | firategrast (SB683699) | “firategrast (SB683699)” NCT00548769 ↗ |
| Known as | SB683699 | “Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients” NCT00548769 ↗ |
| Action | Inhibit | “oral short-acting α4β integrin blockade therapies” PMID 22226929 ↗ Jan 2012 |
| Modality | Small molecule | “firategrast, a small oral anti-α4β-integrin molecule” PMID 22226929 ↗ Jan 2012 |
| Route | Oral | “a small oral anti-α4β-integrin molecule” PMID 22226929 ↗ Jan 2012 |